Skip to main content
    A

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $21.12
    -0.11 (-0.52%)

    Market Cap: $7.40B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a market cap of $7.40B and an enterprise value of $10.42B. Its share count is up 6.86% from a year earlier. Its trailing P/E of 21.3x is above its 10-year median of 10.8x.

    Total Valuation

    Enterprise value is 40.84% above the market cap, as debt exceeds cash.

    Market Cap$7.40B
    Enterprise Value$10.42B
    Latest price (Nov 17, 2026)$21.12

    Key Dates

    The next earnings report is expected on Feb 25, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 25, 2027 (expected)
    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 5.18% in the quarter ended Sep 30, 2026 and grew 4.13% a year over 2 years.

    Shares Outstanding335.73M
    Shares Change (YoY)+6.86%
    Shares Change (QoQ)+5.18%
    Share Count Growth (2Y CAGR)+4.13%

    Valuation Ratios

    Sales and book value multiples are 2.2x and 13.3x. Its year-end P/E ranged from 2.9x to 26.4x from 2016 to 2025.

    P/E Ratio21.3x
    Forward P/E19.8x
    P/S Ratio2.2x
    Forward P/S2.3x
    P/B Ratio13.3x
    P/FCF Ratio184.5x
    P/OCF Ratio41.0x
    PEG Ratio0.9

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 15.2x EBITDA and 263.2x free cash flow.

    EV / Earnings49.7x
    EV / Sales3.3x
    EV / EBITDA15.2x
    EV / EBIT22.9x
    EV / FCF263.2x

    Price Statistics

    The stock is up 81.44% over 52 weeks and trades 6.29% above its 50-day average.

    Beta (1Y)0.64
    52-Week Change+81.44%
    1-Month Change+9.09%
    3-Month Change+16.62%
    6-Month Change+78.83%
    5-Year Change+291.80%
    10-Year Change+7.01%
    Total Return (1Y)+81.44%
    Total Return (3Y CAGR)+67.04%
    Total Return (5Y CAGR)+35.73%
    Return vs SPY (1Y)+70.98%
    Max Drawdown (1Y)-22.25%
    Max Drawdown (3Y)-24.65%
    Sharpe Ratio (1Y)1.73
    Correlation with SPY (1Y)0.25
    50-Day Average$19.87
    200-Day Average$16.17
    52-Week Range$11.45 to $22.07
    RSI (14 Days)55.9
    Average Volume (20 Days)3.85M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.87x current liabilities, and total debt is 5.98x shareholder equity.

    Current Ratio1.87x
    Quick Ratio1.24x
    Debt / Equity5.98x
    Debt / EBITDA4.79x
    Debt / FCF82.72x
    Interest Coverage13.12x

    Returns and Efficiency

    Return on invested capital is 11.58% over the last 12 months, against a 5-year average of 6.43%.

    Return on Equity (ROE)39.43%
    Return on Assets (ROA)3.98%
    Return on Invested Capital (ROIC)11.58%
    Return on Capital Employed (ROCE)10.95%
    ROA (5Y Average)-1.25%
    ROIC (5Y Average)6.43%
    Asset Turnover0.72x
    Inventory Turnover2.76x
    Receivables Turnover3.13x
    Cash Conversion Cycle101 days

    Taxes

    Income tax took 5.40% of pretax income over the last 12 months.

    Income Tax (TTM)$11.96M
    Effective Tax Rate5.40%

    Scores

    AMRX has an Altman Z-Score of 1.92, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score1.92
    Altman Z ZoneGrey
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $3.20B over the last 12 months is up 8.88% from the 12 months before.

    Revenue$3.20B
    Revenue Growth (YoY)+8.88%
    Gross Profit$1.29B
    Operating Income$478.99M
    Pretax Income$221.46M
    Net Income$209.49M
    EBITDA$663.62M
    EBIT$454.28M
    Reported EPS (TTM)$0.99

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 10.08% of the $5.27B in total assets.

    Cash and Equivalents$157.40M
    Total Debt$3.18B
    Net Debt$3.02B
    Net Debt Per Share$9.00
    Working Capital$975.18M
    Shareholder Equity$531.26M
    Book Value Per Share$1.58
    Tangible Book Value-$1.79B
    Total Assets$5.27B
    Total Liabilities$4.63B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $142.20M of capital spending, operating cash flow left $38.42M of free cash flow.

    Operating Cash Flow$180.63M
    Capital Expenditures$142.20M
    Free Cash Flow$38.42M
    FCF Per Share$0.11
    Depreciation and Amortization$209.33M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 14.99%, against a 5-year average of 6.70%.

    Gross Margin40.24%
    Operating Margin14.99%
    Pretax Margin6.93%
    Net Margin6.56%
    EBITDA Margin20.77%
    EBIT Margin14.22%
    FCF Margin1.20%
    Gross Margin (5Y Average)35.98%
    Operating Margin (5Y Average)6.70%
    Net Margin (5Y Average)-2.20%

    Growth

    Revenue grew 10.92% a year over 3 years, and EPS 7.30% a year.

    Revenue Growth (3Y CAGR)+10.92%
    Revenue Growth (5Y CAGR)+8.66%
    EPS Growth (3Y CAGR)+7.30%
    EPS Growth (5Y CAGR)+5.92%
    FCF Growth (3Y CAGR)+145.46%
    FCF Growth (5Y CAGR)-5.33%

    Revenue and profit by year

    Dividends and Yields

    AMRX does not pay a dividend. Its free cash flow yield is 0.54%.

    Earnings Yield4.69%
    FCF Yield0.54%
    Shareholder Yield0.00%

    Peer Position

    Against 11 similar companies, AMRX has the 6th highest P/E.

    P/E Ratio21.3x vs 18.5x median
    P/S Ratio2.2x vs 3.0x median
    ROIC11.58% vs 7.85% median
    Revenue Growth (Trailing 4 Quarters, YoY)+8.88% vs +20.61% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 7.78% and EPS growth at 21.15% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+7.78%
    EPS Growth Forecast (2Y CAGR)+21.15%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About AMRX

    What is AMRX's market cap?

    Amneal Pharmaceuticals, Inc. Class A Common Stock has a market cap of $7.40B. Its enterprise value, which adds debt and subtracts cash, is $10.42B.

    What is AMRX's P/E ratio?

    Amneal Pharmaceuticals, Inc. Class A Common Stock has a trailing P/E ratio of 21.3x and a forward P/E of 19.8x.

    How many shares of AMRX are outstanding?

    Amneal Pharmaceuticals, Inc. Class A Common Stock has 335.73M shares outstanding. The count is up 6.86% from a year earlier.

    Does AMRX pay a dividend?

    No. Amneal Pharmaceuticals, Inc. Class A Common Stock does not pay a dividend.

    How much debt does AMRX have?

    Amneal Pharmaceuticals, Inc. Class A Common Stock has $3.18B of total debt and $157.40M of cash and equivalents, a net debt position of $3.02B.